Primecap Management Co. CA Makes New Investment in Palvella Therapeutics, Inc. $PVLA

Key Points

• Primecap Management acquired 256,182 Palvella Therapeutics shares worth approximately $39.15 million, giving it a 1.78% stake. Institutional investors collectively own 40.11% of PVLA.
• Analyst sentiment is largely positive, with the stock carrying a consensus “Buy” rating and an average price target of $209.14, although Weiss Ratings maintained a “sell” rating.
• Palvella reported quarterly EPS of -$1.52, missing the $1.17 loss analysts expected. Shares opened at $154.33, near their 52-week high of $161.38, while COO Kathleen Goin sold $654,807 worth of shares under a pre-arranged trading plan.

Primecap Management Co. CA purchased a new stake in Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 256,182 shares of the company's stock, valued at approximately $39,150,000. Primecap Management Co. CA owned about 1.78% of Palvella Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Nicholas Investment Partners LP bought a new position in shares of Palvella Therapeutics during the second quarter worth about $7,598,000. Legal & General Group Plc bought a new stake in Palvella Therapeutics in the second quarter valued at approximately $1,222,000. The Manufacturers Life Insurance Company bought a new stake in Palvella Therapeutics in the second quarter valued at approximately $2,376,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Palvella Therapeutics during the 2nd quarter valued at approximately $35,000. Finally, Quantbot Technologies LP acquired a new stake in Palvella Therapeutics during the 2nd quarter valued at approximately $71,000. Institutional investors and hedge funds own 40.11% of the company's stock.

Wall Street Analyst Weigh In

PVLA has been the subject of several analyst reports. Truist Financial set a $207.00 price target on shares of Palvella Therapeutics in a report on Wednesday, August 5th. Chardan Capital upgraded shares of Palvella Therapeutics to a "strong-buy" rating in a research report on Tuesday, July 28th. Canaccord Genuity Group set a $232.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. Stephens reissued an "overweight" rating and set a $220.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $209.14.

Palvella Therapeutics Price Performance

Shares of PVLA opened at $154.33 on Thursday. The stock has a 50-day moving average of $144.53 and a 200-day moving average of $126.25. The company has a market cap of $2.22 billion, a PE ratio of -31.95 and a beta of -0.17. Palvella Therapeutics, Inc. has a one year low of $49.81 and a one year high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35). Analysts expect that Palvella Therapeutics, Inc. will post -6.36 EPS for the current fiscal year.

Insider Activity at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the company's stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $152.21, for a total transaction of $654,807.42. Following the transaction, the chief operating officer directly owned 2,154 shares of the company's stock, valued at $327,860.34. This represents a 66.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is currently owned by corporate insiders.

About Palvella Therapeutics

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source